ADC Therapeutics’ Post

Kymera Therapeutics presents new clinical data from the ongoing Phase 1 trial of potent, highly selective STAT3 Degrader KT-333, a historically undrugged transcription factor at EHA Annual Meeting KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor Well-tolerated with Phase 1 dose escalation ongoing and additional data expected in the second half of 2024 https://lnkd.in/gxFube6Z

Innate Pharma and the IFLI - Institute for Follicular Lymphoma Innovation are pleased to announce a new agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in Follicular Lymphoma. Patients with R/R Follicular Lymphoma will be included in the ongoing Phase 1/2 trial investigating IPH6501 in patients with R/R CD20+ Non-Hodgkin Lymphoma To support Innate and the investigation of IPH6501 in Follicular Lymphoma, the IFLI will invest up to $7.9M. Learn more: https://lnkd.in/gmygWPZU #InnatePharma #ANKET #agreement #FollicularLymphoma

Yesterday, we presented positive initial results from our first-in-human Phase 1 #ClinicalTrial of SYNCAR-001 + STK-009, our orthogonal IL-2 and CD19 #CART investigational therapy, for the treatment of relapsed or refractory CD19+ hematologic malignancies at the 66th American Society of Hematology Annual Meeting and Exposition. Data presented on the combination of STK-009 and a low dose of SYNCAR-001 cells demonstrate a favorable safety profile without dose-limiting or IL-2 related toxicities, as well as durable responses, including complete responses in 4 of 4 patients with non-Hodgkin lymphoma. We are encouraged by the ongoing validation of our orthogonal IL-2 technology and look forward to evaluating SYNCAR-001 + STK-009 in patients without lymphodepleting chemotherapy. Learn more about the results here: https://lnkd.in/gdwcxZbC View the poster here: https://lnkd.in/g7BEhW68

On the World Lymphoma Day, let’s stand united in hope and strength, lighting the path to brighter tomorrows. Together, we conquer! Visit our website to know more: https://lnkd.in/e6sBrr8E #SpreadHope #TogetherAgainstLeukemia #Leukemia #BloodCancer #Biologix #Pioneering #Leading #Engaging#lymphomaawarenessmonth

Today we announced our first abstract on CRG-023 to be presented at the @American Society of Hematology Annual Meeting in San Diego. CRG-023 is a CD19-, CD20- and CD22-targeting tri-specific, tri-cistronic CAR T product candidate designed to provide more patients with a broad range of B-cell malignancies with durable responses, resulting in a potential best-in-class CAR T-cell therapy. Encouraging preclinical data showed sustained, durable anti-B cell lymphoma activity. CRG-023 represents the next step in our mission to develop best-in-class, potentially curative CAR T-cell therapies. Read more about the abstract and poster presentation details here: https://bit.ly/3UD0vlS #ASH24 #celltherapy

Monjuvi improves PFS in r/r follicular lymphoma in phase III trial Incyte announced positive topline results from the phase III inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide (Revlimid) and rituximab (Rituxan) compared to lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma. https://lnkd.in/eSMAne6a

Highlighting Immunotherapy as first line treatment of advance Hodgkin disease A recent trial by Dr. Herrera from City of Hope compared first line treatment of advanced stage Hodgkin lymphoma patients with #Nivolumab or #Brentuximab combined with traditional AVD chemotherapy. The initial result after nearly two year follow-up of approximately 1000 patients showed better progression free survival in patients treated with #Nivolumab. N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin’s lymphoma and had a better side-effect profile. #Hodgkin #Nivolumab #Immunotherapy #Lymphoma https://lnkd.in/d58GVr8t

Two subtypes of cutaneous T-cell lymphoma (#CTCL) - Mycosis Fungoides and Sézary Syndrome - manifest and spread in different ways, including within the blood. Learn more at https://bit.ly/3Z9CSnR #BloodCancerAwarenessMonth

🚨 THIS MONTH: Unlock 🔒 New Strategies: Dive into the use of 🧬 bispecific antibodies for R/R non-Hodgkin lymphoma. Enhance your expertise in their administration, managing adverse effects, and incorporating them into patient care. Reserve Your Spot: http://ms.spr.ly/6046l4yZQ

CALQUENCE plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial. The recent results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE (acalabrutinib) in combination with bendamustine and rituximab demonstrated an improvement in progression-free survival (PFS) and showed a favourable trend in overall survival (OS) compared to standard-of-care chemoimmunotherapy (bendamustine plus rituximab) in previously untreated patients with mantle cell lymphoma (MCL).